Aegerion seeks US, European nods for lipid disorder drug
This article was originally published in Scrip
Executive Summary
Taking aim at drugs like Merck's Vytorin (ezetimibe/simvastatin) in the homozygous familial hypercholesterolemia (HoFH) marketplace, Massachusetts biotech Aegerion Pharmaceuticals is seeking approval in the US and Europe for its lead experimental medicine lomitapide as an adjunct to a low fat diet and other lipid-lowering therapies to reduce cholesterol in patients with the rare genetic lipid disorder.